MedTrace Logo

Genetic Variation in TRAF3IP2 (rs13190932)

NCT07086924 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-07-25

No results posted yet for this study

Summary

Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population.

It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals.

The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.

Conditions

Interventions

DRUG

Methotrexate

Assessing the response of psoriasis and psoriatic arthritis to Methotrexate. and also Assessing the pharmacogenetic association between TRAF3IP2 ( rs13190932 ) gene Polymorphism in psoriatic and psoriatic arthritis patients taking Methotrexate.

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Eisa Mohammed Hegazy, Professor · Dermatology,Venereology,and Andrology Department,Faculty of Medicine,South Valley University, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2026-06-01
Completion
2026-06-10

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07086924 on ClinicalTrials.gov